Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) Overview
Learn About Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Temple Faculty Practice Plan Inc
Henry Fung is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Fung and is rated as an Advanced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Temple Faculty Practice Plan Inc
Jason Incorvati is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Incorvati has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Philadelphia-Negative Chronic Myeloid Leukemia.
Temple Faculty Practice Plan Inc
Shelly Hayes is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Hayes and is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Familial Prostate Cancer, Laryngeal Cancer, Throat Cancer, and Posterior Fossa Tumor.
Summary: This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cel...
Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with NLPHL. Secondary Objective: * To examine differences in baseline and longitudinal changes in PROs based on disease characteristics, disease status, and treatment strategies among adult and pediat...